Publication

Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus

Schaper, F., de Leeuw, K., Horst, G., Maas, F., Bootsma, H., Heeringa, P., Limburg, P. C. & Westra, J., Jun-2017, In : Clinical and Experimental Immunology. 188, 3, p. 412-419 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus

    Final publisher's version, 269 KB, PDF-document

DOI

Autoantibodies to nuclear structures are a hallmark of systemic lupus erythematosus (SLE), including autoantibodies to nuclear protein high mobility group box 1 (HMGB1). HMGB1 consists of three separate domains: box A, box B and an acidic tail. Recombinant box A acts as a competitive antagonist for HMGB1 and might be an interesting treatment option in SLE. However, antibodies to box A might interfere. Therefore, levels of anti-box A were examined in SLE patients in association with disease activity and clinical parameters. Serum anti-box A was measured in 86 SLE patients and 44 age- and sex-matched healthy controls (HC). Serum samples of 28 patients with primary Sjogren's syndrome and 32 patients with rheumatoid arthritis were included as disease controls. Anti-HMGB1 and anti-box B levels were also measured by enzyme-linked immunosorbent assay during quiescent disease [SLE Disease Activity Index (SLEDAI) = 5, n=39). Anti-box A levels in active SLE patients were higher compared to quiescent patients, and were increased significantly compared to HC and disease controls. Anti-box A levels correlated positively with SLEDAI and anti-dsDNA levels and negatively with complement C3 levels. Increased levels of anti-box A antibodies were present in the majority of patients with nephritic (73%) and non-nephritic exacerbations (71%). Antibodies to the box A domain of HMGB1 might be an interesting new biomarker, as these had a high specificity for SLE and were associated with disease activity. Longitudinal studies should be performed to evaluate whether these antibodies perform better in predicting an exacerbation, especially non-nephritic exacerbations.

Original languageEnglish
Pages (from-to)412-419
Number of pages8
JournalClinical and Experimental Immunology
Volume188
Issue number3
Early online date9-May-2017
Publication statusPublished - Jun-2017

    Keywords

  • anti-box A, anti-HMGB1, autoantibodies, HMGB1, SLE, CHROMOSOMAL-PROTEIN 1, DISEASE-ACTIVITY, ANTI-HMGB1 ANTIBODIES, CYTOKINE RELEASE, RECEPTOR 4, ARTHRITIS, MICE, NEPHRITIS, CLASSIFICATION

View graph of relations

ID: 40225620